Physician profile
Lisa Mercado
NPI 1770181182
$2,836.75
in general payments reported to CMS, 2019-2025
22 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.29 · 2022: $524 · 2023: $1,172 · 2024: $449 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $693.69 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $511.59 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $310.54 | 2021-2022 | |
| Atricure, INC. | $196.93 | 2023 | |
| Sumitomo Pharma America, INC. | $187.21 | 2023 | Gemtesa, Aptiom |
| Novo Nordisk INC | $124.47 | 2023 | |
| Vanda Pharmaceuticals INC. | $123.05 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $107.31 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $98.65 | 2021-2025 | Amyvid, Kisunla |
| Ucb, INC. | $95.15 | 2024-2025 | Briviact, Nayzilam |
| Medtronic, INC. | $74.28 | 2023 | Venaseal |
| Acadia Pharmaceuticals INC | $63.10 | 2021-2023 | Nuplazid |
| Ardelyx, INC. | $53.12 | 2024-2025 | Ibsrela |
| Neurelis, INC. | $43.66 | 2022-2023 | Valtoco |
| Axsome Therapeutics, INC. | $30.54 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $26.10 | 2023 | |
| Indivior INC. | $19.32 | 2023 | Perseris |
| Kyowa Kirin, INC. | $17.91 | 2022 | |
| Lundbeck LLC | $16.16 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $15.68 | 2022 | |
| Sun Pharmaceutical Industries INC. | $14.40 | 2021 | |
| Merck Sharp & Dohme LLC | $13.89 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.